Quality of Life
Areas of the most intense research for lupus include genetics, and treatments. Every lupus patient should have their Vitamin D status regularly tested and their levels optimized. (Also see Autoimmune Diseases, Overview of Lupus, Difficult Diagnosis, What is Scleroderma?, and Overlap Syndrome)
Correlation between the changes of innate lymphoid cells (ILCs) in peripheral blood of systemic lupus erythematosus (SLE) and its clinical significance. The percentage of ILCs is related to disease activity, and ILCs play a “double-edged” role in the pathogenesis of SLE. PubMed, Zhonghua Yi Xue Za Zhi, 2019 Jan 15;99(3):169-173.
Progressive reduction of serum complement levels: a risk factor for relapse in patients with hypocomplementemia in systemic lupus erythematosus (SLE). Simultaneous progressive reductions in complement levels and increases in anti-dsDNA antibody levels may indicate future relapse of serologically active clinically quiescent–SLE patients. PubMed, Lupus, 2018 Oct 11:961203318804892.
Adipokine interactions promote the pathogenesis of systemic lupus erythematosus (SLE). Adipokines levels and associated clinical manifestations suggest involvement of adipokines in disease pathogenesis of SLE. PubMed, Cytokine, 2018 Aug 8;111:20-27.
Serum level of DNase1l3 in patients with dermatomyositis/polymyositis (DM/PM), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), and its association with disease activity. A significant reduction was found in serum DNase1l3 level in DM/PM and SLE, which may associate with clinic features and disease activity. PubMed, Clin Exp Med, 12/30/2016. (Also see Dermatomyositis and Polymyositis and Causes of Rheumatoid Arthritis)
Adipokines, tumor necrosis factor (TNF) and its receptors in female patients with systemic lupus erythematosus (SLE). The correlation between adipokines and TNF system allows a better understanding of the role of adipokines in the inflammatory response in SLE patients. PubMed, Lupus, 06/30/2016.
Full high–throughput sequencing analysis of differences in expression profiles of long noncoding RNAs and their mechanisms of action in systemic lupus erythematosus. This work determined specific lncRNAs that play important biological functions in the pathogenesis of lupus and provided a new direction for diagnosis and treatment of disease. PubMed, Arthritis Res Ther, 2019 Mar 5;21(1):70.
The Synergistic Effect of TNFA and IL10 Promoter Polymorphisms on Genetic Predisposition to Systemic Lupus Erythematosus (SLE). Our findings suggest that the combinatorial complexity of TNFA and IL10 promoter polymorphisms impacts SLE susceptibility. PubMed, Genet Test Mol Biomarkers, 01/03/2018.
Microbiota and oxidant–antioxidant balance in systemic lupus erythematosus. These results could be useful in the future to go deeper into the understanding of this complex disease. PubMed, Nutr Hosp, 2017 Jul 28;34(4):934-941.
The microbiome and systemic lupus erythematosus (SLE). Elucidation of the roles of gut microbes in SLE will shed light on how this autoimmune disorder develops. PubMed, Immunol Res, 2017 Apr;65(2):432-437.
Role of neutrophil dysfunction in the pathogenesis of systemic lupus erythematosus. There is evidence for further investigations of neutrophil-mediated pathogenetic processes in SLE in order to identify potential therapeutic targets and to understand the mechanisms of action of drugs used in clinical practice. PubMed, Ter Arkh, 2017;89(12):110-113.
miR-210 expression in PBMCs from patients with systemic lupus erythematosus and rheumatoid arthritis. The dysregulation of miR-210 levels in SLE and RA patients suggests that miR-210 might play an important role in the pathogenesis of these diseases. PubMed, Ir J Med Sci, 05/30/2017. (Also see Symptoms and Complications of Rheumatoid Arthritis)
Y-27632, a Rho–associated protein kinase inhibitor, inhibits systemic lupus erythematosus. The findings showed that the inhibition of rho-associated, coiled–coil–containing protein kinase 1(ROCK) was beneficial for the prevention of systemic lupus erythematosus, which possibly by suppressing NF-?B activation. PubMed, BioMed Pharmacother, 2017 Apr;88:359-366. (Also see Interleukins)
Impact of the leucocyte immunoglobulin-like receptor A3 (LILRA3) on susceptibility and subphenotypes of systemic lupus erythematosus (SLE) and Sjögren's syndrome (pSS). Functional LILRA3 is a new susceptibility factor for SLE and pSS and it highly predisposes to certain phenotypes such as leucopenia, thrombocytopenia and autoantibody-positive subphenotypes. PubMed, Ann Rheum Dis. (Also see Sjögren's Syndrome Research)
Prevalence of depression and anxiety in systemic lupus erythematosus (SLE): a systematic review and meta–analysis. The prevalence of depression and anxiety was high in adult SLE patients. PubMed, BMC Psychiatry, 2017 Feb 14;17(1):70. (Also see Anxiety and Attitude)
Serum 25–OH vitamin D level in treatment–naïve systemic lupus erythematosus (SLE) patients: Relation to disease activity, IL-23 and IL-17. Hypovitaminosis D contributes to ANA antibody production and is associated with high serum levels of IL-23 and IL-17 and may trigger the inflammatory process in SLE. Lupus, 12/07/2016. (Also see Interleukins)
TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.
We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: